Table 1 Patient Demographics
From: Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia
Total Cases (N = 28) | VTE Cases (N = 15) | AF cases (N = 13) | P value € | |
|---|---|---|---|---|
Cases per Centre, range (median) | 0–12 (2) | 0–7 (1) | 0–5 (2) | – |
Age, years, range (median) | 30–84 (65) | 30–75 (57) | 53–84 (71) | 0.0061 |
Males, N (%) | 13 (46.4%) | 3 (20%) | 10 (76.9%) | 0.0031 |
Pulmonary AVMs (%) | 6 (21.4%) | 6 (40%) | 0 (0%) | 0.010 |
Hepatic AVMs (%)† | 15 (75%) | 5/8 known (63%) | 10/12 known (83.3%) | 0.30 |
Cerebral AVMs (%) ‡ | 3 (16.7%) | 2/10 known (20%) | 1/8 known (12.5%) | 0.68 |
DOAC episodes per patient, range (median) | 1–3 (1) | 1–3 (1) | 1–1 (1) | – |
DOAC cases also treated with warfarin | 7 | 3 | 4 | – |